Evidence map›Paper›PMID 33450877›Full record

ReviewToxins2021

A Review of the Efficacy of FDA-Approved

Zoe Couse, Xizhong Cui, Yan Li, Mahtab Moayeri, Stephen Leppla, Peter Q Eichacker

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Toxins, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Zoe CouseCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
Xizhong CuiCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
Yan LiCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
Mahtab MoayeriNational Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Stephen LepplaNational Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Peter Q EichackerCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
National Institutes of Health Clinical Center · USNational Institutes of Health · US

Funding

Pathophysiological Actions of the Anthrax ToxinsZIAAI001032 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI LEPPLA, STEPHEN · 2009 to 2025
$10.9M
CDC HHS n/aDivision of Intramural Research, National Institute of Allergy and Infectious Diseases n/aNIH Clinical Center n/aU.S. Food and Drug Administration n/a
6 · The paper itself

Abstract

Anti-toxin agents for severe

Indexed as

Antigens, BacterialBacterial ToxinsAnimalsAnthraxAnti-Bacterial AgentsAntibodies, MonoclonalAntitoxinsBacillus anthracisDisease Models, AnimalDogsDrug Evaluation, PreclinicalDrug Therapy, CombinationHemodynamicsHumansImmunoglobulins, IntravenousShock, Septicanthrax toxinAnti-Bacterial AgentsAntibodies, MonoclonalAntigens, BacterialAntitoxinsBacterial ToxinsImmunoglobulins, Intravenousanthraxantibiotic supportanti-toxinB. anthracishemodynamic supportlethal and edema toxinshock

Identifiers

PMID33450877
PMCPMC7828353
OpenAlexW3119761513

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.